Research Archivi - Page 4 of 10

Pathology Cluster

Year

Spoke

Impairment of oxidative metabolism compromises Rad51 recruitment and potentiates PARP inhibitor effectiveness in ovarian cancer

2026 Spoke 3 Oncology and innovative therapies Preclinical studies on fundamental disease mechanisms

Laura Formenti, Francesca Abramo, Giulia Dellavedova, Valentina Dematteis, Alessandra Decio, Chiara Grasselli, Paola Fabbrizio, Laura Brunelli, Raffaella Giavazzi, Carmen Ghilardi

The Two-Way Role of Jagged1 in Cancer: A Focus on CRC

2025 Spoke 4 Oncology and innovative therapies

Zema, S., Di Fazio, F., Palermo, R., Talora, C., & Bellavia, D.

Rationalizing the structural basis of organic-platinum hybrid complexes binding towards quadruplex-duplex hybrids through all-atom simulations

2025 Spoke 3 Advanced technologies and experimental models

Salvatore Muscarella, Irene Treccarichi, Luisa D’Anna, Angelo Spinello

Astrocytes differentiated from patient iPSCs model the rare leukodystrophy MLC and uncover disease-linked maturation defects and Kir4.1 channel dysfunction

2026 Spoke 3 Rare diseases and genetic disorders

Angela Lanciotti, Maria Stefania Brignone, Chiara De Nuccio, Sara Sposito, Elena Sofia Caprini, Marcello Belfiore, Francesco Nicita, Caterina Veroni, Chiara Meloni, Rosalba Carrozzo, Teresa Rizza, Chiara Aiello, Jacopo Sartorelli, Enrico Bertini, Sergio Visentin, Elena Ambrosini

Glial Ion Channels in Myelin Pathophysiology: Insights from Leukodystrophies

2025 Spoke 3 Rare diseases and genetic disorders Preclinical studies on fundamental disease mechanisms

Belfiore M, Visentin S, Ambrosini E.

PGC-1α: key regulator of mitochondrial biogenesis and cellular differentiation in metabolic and regenerative tissues

2025 Spoke 3 Preclinical studies on fundamental disease mechanisms

Lijuan Cao, Yanan Li, Artem Smirnov, Ramouna Voshtani, Tingting Wang, Changshun Shao, Eleonora Candi, Gerry Melino, Yufang Shi, Jiankai Fang

Decoding cancer dormancy: integrative genomic, phenotypic and live-cell imaging analysis to reveal the hidden cancer cell reservoir

2025 Spoke 3 Oncology and innovative therapies

Gaetana Porcelli, Caterina D’Accardo, Francesca Angeloro, Martina Cucchiara, Paola Bianca, Vincenzo Davide Pantina, Narges Roozafzay, Chiara Modica, Miriam Gaggianesi, Sebastiano Di Bella, Giorgio Stassi, Alice Turdo, Matilde Todaro

Adipocyte/Tumor cell crosstalk via IGF-1/TXNIP axis promotes malignancy and endocrine resistance in breast cancer

2025 Spoke 3 Oncology and innovative therapies

Amanda Caruso, Felice Maria Accattatis, Cinzia Giordano, Luca Gelsomino, Piercarlo Del Console, Maria Francesca Fiorita, Balazs Gyorffy, Laura Bianchi, Alfonso Carleo, Rossana De Salvo, Bruno M Simões, Robert B Clarke, Lorenzo Memeo, Cristina Colarossi, Eleonora Aiello, Francesco Conforti, Suzanne A W Fuqua, Matilde Todaro, Giorgio Stassi, Catia Morelli, Diego Sisci, Daniela Bonofiglio, Stefania Catalano, Sebastiano Andò, Ines Barone

Protocol to investigate cell cycle-dependent modes of micronucleus formation using dual-pulse nascent DNA labeling

2025 Spoke 3

Pepe S, Duardo RC, Capranico G, Marinello J.

Mesenchymal stromal cells highly expressing Sca-1 promote breast cancer lung metastasis through recruiting myeloid cells

2025 Spoke 3 Oncology and innovative therapies

Lijuan Cao, Yanan Li, Minghui Ou, Artem Smirnov, Rui Liu, Tingting Wang, Xiao Su, Peishan Li, Mancini Mara, Eleonora Candi, Zhiyuan Zheng, Gerry Melino, Changshun Shao, Yufang Shi

Rheology and Printability of Hydroxyapatite/Sodium Alginate Bioinks Added with Bovine or Fish Collagen Peptides

2025 Spoke 3 Advanced technologies and experimental models

Milazzo M, Rovelli R, Ricci C, Macchi T, Gallone G, Danti S.

Rheological Characterization of Marine and Bovine Collagen Peptides/Acetic Acid Slurries Incorporating Hydroxyapatite Nanoparticles

2025 Spoke 3 Advanced technologies and experimental models

Mario Milazzo, Claudio Ricci, Eugenio Redolfi Riva, Damiano Rossi, Irene Anguillesi, Maurizia Seggiani, Giuseppe Gallone, Serena Danti

The role of 3D preclinical models in the Era of precision medicine: A bladder cancer perspective

2026 Spoke 3

Carlotta Frascolla, Riccardo Mastroianni, Giuseppe Simone, Giovanni Blandino

Dissecting endometrial cancer complexity in response to standard and targeted therapies

2025 Spoke 3 Oncology and innovative therapies

Sebastiano Vaccarella, Valentina Bruno, Giulia Orlandi, Daniela Angela Covino, Carlotta Frascolla, Claudio Pulito, Riccardo Vizza, Giulia Urbani, Matteo Allegretti, Valentina De Pascale, Frauke Goeman, Ludovica Ciuffreda, Brindusa Ana Maria Arteni, Simona Di Martino, Andrea Sacconi, Emanuela Mancini, Anna Bagnato, Ermelinda Baiocco, Ramy Kajal, Yaron Vinik, Sima Lev, Maurizio Fanciulli, Antonello Vidiri, Mariantonia Carosi, Sabrina Strano, Sara Donzelli, Enrico Vizza, Giovanni Blandino

Agent-based modeling of macrophage-fibroblast interactions in the immune response to biomaterials

2025 Spoke 2 Advanced technologies and experimental models

Jennifer Riccio, Luca Presotto, Shir Bahiri, Liad Doniza, Donato Inverso, Laura Sironi, Uri Nevo, Giuseppe Chirico

Computational approaches for modelling multidrug efflux pumps of the resistance nodulation-cell division superfamily

2025 Spoke 2

Athar M, Gervasoni S, Malloci G, Ruggerone P, Vargiu AV,

Rethinking genomics of facioscapulohumeral muscular dystrophy in the telomere-to-telomere era: pitfalls in the hidden landscape of D4Z4 repeats

2026 Spoke 2

Salsi, V., Losi, F., Pini, S., Chiara, M and Tupler R.

Integrating multi-omics data: Methods and applications in human complex diseases

2025 Spoke 2

Pasquale Sibilio, Enrico De Smaele, Paola Paci, Federica Conte.

Prioritizing repurposable drugs for Alzheimer’s disease using network-based analysis with concurrent assessment of Long QT syndrome risk

2025 Spoke 2 Neurodegenerative diseases

Alessio Funari, Enrico De Smaele, Paola Paci, Giulia Fiscon.

High-resolution conditional MR image synthesis through the PACGAN framework

2025 Spoke 2 Advanced diagnostics

Lai M, Marzi C, Citi L, Diciotti S.

Pulmonary Emphysema at Low-Dose CT Lung Cancer Screening: Assessment Tools and AI Challenges

2025 Spoke 2 Respiratory system and related systemic diseases Oncology and innovative therapies

Mascalchi M, Diciotti S.

Nuclear respiratory factor 1 promotes cell survival in multiple myeloma under proteasome inhibition therapy

2025 Spoke 2 Oncology and innovative therapies

Tiziana Bruno, Maria Chiara Cappelletto, Clelia Cortile, Stefano Di Giovenale, Bruno Amadio, Francesca De Nicola, Italia Falcone, Stefano Giuliani, Belinda Palermo, Valeria Catena, Ludovica Ciuffreda, Fulvia Cerruti, Paolo Cascio, Roberta Merola, Serena Masi, Valentina De Pascale, Ombretta Annibali, Silvia Ferraro, Svitlana Gumenyuk, Francesco Pisani, Francesco Marchesi, Andrea Mengarelli, Maurizio Fanciulli, Giacomo Corleone.

Epigenetic priming of an epithelial enhancer by p63 and CTCF controls expression of a skin-restricted gene XP33

2023 Spoke 1 Preclinical studies on fundamental disease mechanisms

Smirnov A, Lena AM, Tosetti G, Yang X, Cappello A, Helmer Citterich M, Melino G, Candi E.

Alleviating hypoxia to improve cancer immunotherapy

2023 Spoke 1 Oncology and innovative therapies

Fan P, Zhang N, Candi E, Agostini M, Piacentini M; TOR Centre; Shi Y, Huang Y, Melino G.

Mucinous and Signet-Ring Cell Colonic Adenocarcinoma in Inflammatory Bowel Disease: A Case-Control Study

2023 Spoke 1 Metabolic diseases and systemic inflammation Oncology and innovative therapies

Neri B, Mancone R, Savino L, Schiavone S, Formica V, Pizzi F, Salvatori S, Mossa M, Migliozzi S, Fiorillo M, Morelli C, Moscardelli A, Lolli E, Calabrese E, Sica GS, Monteleone G, Biancone L.

Transglutaminase Type 2-MITF axis regulates phenotype switching in skin cutaneous melanoma

2023 Spoke 1 Oncology and innovative therapies Preclinical studies on fundamental disease mechanisms

Muccioli S, Brillo V, Varanita T, Rossin F, Zaltron E, Velle A, Alessio G, Angi B, Severin F, Tosi A, D’Eletto M, Occhigrossi L, Falasca L, Checchetto V, Ciaccio R, Fascì A, Chieregato L, Rebelo AP, Giacomello M, Rosato A, Szabò I, Romualdi C, Piacentini M, Leanza L.

Targeting Syntaxin 17 to Improve Mitophagy in Heart Failure

2023 Spoke 1 Preclinical studies on fundamental disease mechanisms

Forte M, Sarto G, Sciarretta S.

Longitudinal serum bicarbonate and mortality risk in older patients with advanced chronic kidney disease: analyses from the EQUAL cohort

2024 Spoke 1 Metabolic diseases and systemic inflammation

Lombardi G, Chesnaye NC, Caskey FJ, Dekker FW, Evans M, Heimburger O, Pippias M, Torino C, Szymczak M, Drechsler C, Wanner C, Gambaro G, Stel VS, Jager KJ, Ferraro PM; EQUAL study investigators.

An Investigation of Metabolic Risk Factors and Gut Microbiota in Unexplained Syncope

2024 Spoke 1 Metabolic diseases and systemic inflammation

Longo S, Del Chierico F, Scanu M, Toto F, Legramante JM, Rizza S, Putignani L, Federici M.

SMAD7 Sustains XIAP Expression and Migration of Colorectal Carcinoma Cells

2024 Spoke 1 Oncology and innovative therapies Preclinical studies on fundamental disease mechanisms

Colella M, Iannucci A, Maresca C, Albano F, Mazzoccoli C, Laudisi F, Monteleone I, Monteleone G.

Autophagy and Programmed Cell Death Modalities Interplay in HIV Pathogenesis

2025 Spoke 1 Infectious diseases and Immunology Preclinical studies on fundamental disease mechanisms

Lamsira HK, Sabatini A, Ciolfi S, Ciccosanti F, Sacchi A, Piacentini M, Nardacci R.

Neutralization of acyl coenzyme A binding protein for the experimental prevention and treatment of hepatocellular carcinoma

2025 Spoke 1 Oncology and innovative therapies Preclinical studies on fundamental disease mechanisms

Li S, Motiño O, Lambertucci F, Pol J, Chen H, Pan L, Durand S, Rossin F, Campani C, Poupel L, Klein C, Montégut L, Pérez-Lanzón M, Anagnostopoulos G, Nogueira-Recalde U, Cerone A, Aprahamian F, Dong Y, Lizarralde-Guerrero M, Xue E, Liu P, Zhao L, Pan H, Carbonnier V, Lachkar S, Saavedra Díaz EG, Sun L, Desdouets C, Colnot S, Kepp O, Martins I, Zitvogel L, Piacentini M, Nault JC, Maiuri MC, Zucman-Rossi J, Kroemer G.

Normal hearing function genetics: have you heard all about it? An integrated approach of genome-wide association studies and transcriptome-wide association studies in three Italian cohorts

2025 Spoke 1 Preclinical studies on fundamental disease mechanisms

Santin A, Pianigiani G, Gialluisi A, Pecori A, Spedicati B, Costanzo S, Persichillo M, Bracone F, Nardone GG, Tesolin P, Lenarduzzi S, Morgan A, De Curtis A, van der Valk W, Rousset F, Roccio M, Locher H, Iacoviello L, Concas MP, Girotto G.

MAPK Signaling in the Interplay Between Oxidative Stress and Autophagy

2025 Spoke 1 Preclinical studies on fundamental disease mechanisms

Desideri E, Castelli S, Ciriolo MR.

Malnutrition Is Associated with Increased Liver Stiffness in Type 2 Diabetes: The Mediating Role of Inflammation.

2025 Spoke 1 Metabolic diseases and systemic inflammation

Lo Buglio A, Bellanti F, Villani R, Capurso C, Magnati GP, Cioffi S, Tedesco G, Torsello CA, Vendemiale G, Serviddio G.

A New Algal Friendly Extract from Euglena cantabrica with Potential Applications in Biomedical Field

2025 Spoke 1 Spoke 3 Advanced technologies and experimental models

Buonvino S, Trinca C, Leu S, Licoccia S, Melino S.

Targeting Cancer Cell Energy Metabolism in Colorectal Cancer: Opportunities and Challenges from Drug Repositioning

2025 Spoke 1 Oncology and innovative therapies Preclinical studies on fundamental disease mechanisms

Tomassini L, Pacifico T, Monteleone G, Stolfi C, Laudisi F

Effect of pesticides on breast cancer tum

2025 Spoke 1 Spoke 3 Oncology and innovative therapies Preclinical studies on fundamental disease mechanisms

Marcoccia D, Palomba S, Brajon G, Baldi A, Galli FS, Servadei F, Palumbo V, Bonfiglio R, Treglia M, Marsella LT, Botti F, Shi Y, Candi E, Melino G, Mauriello A, Scimeca M.

Evidence of fructose metabolism in colorectal cancer

2025 Spoke 1 Spoke 3 Oncology and innovative therapies Preclinical studies on fundamental disease mechanisms

Sica GS, Bischof J, Funke L, Hartmut J, Candi E, Mauriello A, Scimeca M, Gao X, Savino L, Servadei F, Yang R, Wang L, Zhao Q, Chen WL, Sun Q, Jia W, Melino G.

Prevention of hydrocephalus with a small oligonucleotide. Mol Ther.

2026 Spoke 3

Lilit Antonyan, Linda Bossini, Xin Zhang, Anjie Ni, Marc-Daniel Hagel, Eva Baronchelli, Martina Geusa, Huashan Peng, Amelia Semenak, Peter Fleming, Shaima Alsuwaidi, Ying Zhang, Beili Hu, Diletta Fontana, Valentina Crippa, Stefania Codazzi, Julia Macintosh, Andres Arriaga-Sierra, Basil Khan, Nuwan Hettige, Malvin Jefri, Yijing Liang, Stephanie Klein, André du Toit, Nhu T N Phan, Andreas Schuppert, Yang Zhou, Rocco Piazza, Keith Murai, Sebastien Jacquemont, Alessandro Sessa, Carl Ernst

Fetal-restricted hematopoietic progenitors arise from hemogenic endothelium in vitelline and umbilical arteries.

2026 Spoke 3

Cristiana Barone, Giulia Quattrini, Alessandro Muratore, Giorgio Anselmi, Yurim Park, Naeema T Mehmood, Elena Morganti, Roberto Orsenigo, Filipa Timóteo-Ferreira, Anna Cazzola, Arianna Patelli, Thea Milanesi, Bianca Nesti, Francisca Soares-da-Silva, Matthew Nicholls, Gloria Zambelli, Mario Mauri, Silvia Bombelli, Sofia De Marco, Deborah D’Aliberti, Silvia Spinelli, Veronica Bonalume, Alison Domingues, Mahdieh Naghavi Alhosseini , Gianluca Sala, Arianna Colonna, Elisabetta D’Errico, Cristina D’Orlando, Cristina Bianchi, Roberto A Perego, Raffaella Meneveri, Ana Cumano, Silvia Brunelli, Marella F T R De Bruijn, Andrea Ditadi, Alessandro Fantin, Rocco Piazza, Emanuele Azzoni

Evolution of transcriptomic profiles in relapsed inv(16) acute myeloid leukemia.

2024 Spoke 1 Oncology and innovative therapies

Travaglini S, Silvestrini G, Attardi E, Fanciulli M, Scalera S, Antonelli S, Maurillo L, Palmieri R, Divona M, Ciuffreda L, Savi A, Paterno G, Ottone T, Barbieri C, Maciejewski JP, Gurnari C, Ciliberto G, Voso MT.

Metabolic Signature of FLT3-Mutated AML: Clinical and Therapeutic Implications.

2025 Spoke 1 Spoke 3

Banella C, Catalano G, Calvani M, Candi E, Noguera NI, Travaglini S.

The WWP1–JARID1B axis sustains acute myeloid leukemia chemoresistance.

2025 Spoke 1 Spoke 3 Oncology and innovative therapies Preclinical studies on fundamental disease mechanisms

Claudia Fierro, Sara Giovannini, Valeria Moriconi, Claudia Fiorilli, Emanuele Panatta, Valentina Frezza, Federica Corigliano, Rosalba Pecorari, Yanan Li Ji Zhou, Vincenza Simona Delvecchio, Artem Smirnov, Jose Manuel Garcia Manteiga, Andrea Brendolan, Jinping Zhang, Yufang Shi, Ivano Amelio, Eleonora Candi, Gerry Melino, Francesca Bernassola

The role of HECT-type E3 ubiquitin ligases in DNA damage response and repair. Cell Death Discov.

2025 Spoke 1 Spoke 3 Preclinical studies on fundamental disease mechanisms

Giovannini S, Fiorilli C, Moriconi V, Shi Y, Candi E, Melino G, Bernassola F.

p63: a crucial player in epithelial stemness regulation.Oncogene.

2023 Spoke 1 Preclinical studies on fundamental disease mechanisms

Yanan Li, Sara Giovannini, Tingting Wang, Jiankai Fang, Peishan Li, Changshun Shao, Ying Wang; TOR centre, Yufang Shi, Eleonora Candi, Gerry Melino, Francesca Bernassola

Predicting and Treating Pulmonary Fibrosis with Proteomic Biomarker Investigations. Biomedicines

2025 Spoke 7 Respiratory system and related systemic diseases

Raineri G, Samarelli AV, Tonelli R, Masciale V, Aramini B, Petrachi T, Bruzzi G, Gozzi F, Trasforini E, Esposito A, Azzali F, Dominici M, Eccher A, Cerri S, Clini E.

Pharmacological inhibition of tyrosine protein-kinase 2 reduces islet inflammation and delays type 1 diabetes onset in mice. EBioMedicine.

2024 Spoke 8 Metabolic diseases and systemic inflammation

Farooq Syed, Olivia Ballew, Chih-Chun Lee, Jyoti Rana, Preethi Krishnan, Angela Castela, Staci A Weaver, Namratha Shivani Chalasani, Sofia F Thomaidou, Stephane Demine, Garrick Chang, Alexandra Coomans de Brachène, Maria Ines Alvelos, Lorella Marselli, Kara Orr, Jamie L Felton, Jing Liu, Piero Marchetti, Arnaud Zaldumbide, Donalyn Scheuner, Decio L Eizirik, Carmella Evans-Molina

Harnessing sulfur- doped carbon nanodots conjugated with IDO inhibitors act as a dual-mode breast cancer immunotherapy. J Control Release.

2025 Spoke 6 Oncology and innovative therapies

Cillari R, Acúrcio RC, Barateiro A, Florindo HF, Mauro N, Cavallaro G.

Nucleolar FRG2 lncRNAs inhibit rRNA transcription and cytoplasmic translation, linking FSHD to dysregulation of muscle-specific protein synthesis.

2025 Spoke 2 Preclinical studies on fundamental disease mechanisms

Valentina Salsi, Francesca Losi, Bruno Fosso, Marco Ferrarini, Sara Pini, Marcello Manfredi, Gaetano Vattemi, Tiziana Mongini, Lorenzo Maggi, Graziano Pesole, Anthony K Henras, Paul D Kaufman, Brian McStay, Rossella Tupler